
Phase II studies of new medical treatments often use historical data on the standard treatment for comparative zzso zzso zzso inherent zzso in the historical data may lead to erroneous conclusions regarding the efficacy of the experimental zzso We propose an approach to phase II trial design which accounts for both zzso and zzso zzso Our results indicate that it is sometimes best to zzso a proportion of the patients to a control zzso We choose this proportion to maximize the precision of the estimated experimental treatment zzso We evaluate operating characteristics of the design zzso and provide illustrations based on historical data from cancer chemotherapy zzso 

